Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

Join over 14,000 individuals and families managing food allergies who are sharing their food allergy stories and making a ...

Otulfi represents the fourth US biosimilar approval for Fresenius Kabi, with the company having already marketed its own ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...

Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment of $850 million.

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...